TY - JOUR
T1 - Large cell calcifying Sertoli cell tumour
T2 - a contemporary multi-institutional case series highlighting the diagnostic utility of PRKAR1A immunohistochemistry
AU - Anderson, William J.
AU - Gordetsky, Jennifer B.
AU - Idrees, Muhammad T.
AU - Al-Obaidy, Khaleel I.
AU - Kao, Chia Sui
AU - Cornejo, Kristine M.
AU - Wobker, Sara E.
AU - Cheville, John C.
AU - Vargas, Sara O.
AU - Fletcher, Christopher D.M.
AU - Hirsch, Michelle S.
AU - Acosta, Andrés M.
N1 - Publisher Copyright:
© 2021 John Wiley & Sons Ltd
PY - 2021
Y1 - 2021
N2 - Aims: Large cell calcifying Sertoli cell tumour (LCCSCT) is a rare testicular sex cord-stromal tumour that primarily affects young patients and is associated with Carney complex. We sought to characterise the clinicopathological features of a series of LCCSCT and evaluate the diagnostic utility of PRKAR1A immunohistochemistry (IHC). Methods and results: The LCCSCT cohort (n = 15) had a median age of 16 years (range = 2–30 years). Four patients were known to have Carney complex. PRKAR1A IHC was performed in each case. For comparison, PRKAR1A IHC was also assessed in other sex cord-stromal tumours, including Sertoli cell tumour, not otherwise specified (SCT, NOS; n = 10), intratubular large cell hyalinising Sertoli cell tumour (n = 1) and Leydig cell tumour (n = 23). Loss of cytoplasmic PRKAR1A expression was observed in all but one LCCSCT (14 of 15; 93%). PRKAR1A expression was retained in all SCTs, NOS (10 of 10; 100%), the majority of Leydig cell tumours (22 of 23; 96%) and an intratubular large cell hyalinising Sertoli cell tumour (1 of 1; 100%). One Leydig cell tumour showed equivocal staining (multifocal weak expression). Conclusions: Overall, PRKAR1A loss is both sensitive (93%) and highly specific (97%) for the diagnosis of LCCSCT. PRKAR1A loss may aid its diagnosis, particularly in sporadic cases and those that are the first presentation of Carney complex.
AB - Aims: Large cell calcifying Sertoli cell tumour (LCCSCT) is a rare testicular sex cord-stromal tumour that primarily affects young patients and is associated with Carney complex. We sought to characterise the clinicopathological features of a series of LCCSCT and evaluate the diagnostic utility of PRKAR1A immunohistochemistry (IHC). Methods and results: The LCCSCT cohort (n = 15) had a median age of 16 years (range = 2–30 years). Four patients were known to have Carney complex. PRKAR1A IHC was performed in each case. For comparison, PRKAR1A IHC was also assessed in other sex cord-stromal tumours, including Sertoli cell tumour, not otherwise specified (SCT, NOS; n = 10), intratubular large cell hyalinising Sertoli cell tumour (n = 1) and Leydig cell tumour (n = 23). Loss of cytoplasmic PRKAR1A expression was observed in all but one LCCSCT (14 of 15; 93%). PRKAR1A expression was retained in all SCTs, NOS (10 of 10; 100%), the majority of Leydig cell tumours (22 of 23; 96%) and an intratubular large cell hyalinising Sertoli cell tumour (1 of 1; 100%). One Leydig cell tumour showed equivocal staining (multifocal weak expression). Conclusions: Overall, PRKAR1A loss is both sensitive (93%) and highly specific (97%) for the diagnosis of LCCSCT. PRKAR1A loss may aid its diagnosis, particularly in sporadic cases and those that are the first presentation of Carney complex.
UR - http://www.scopus.com/inward/record.url?scp=85122289686&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122289686&partnerID=8YFLogxK
U2 - 10.1111/his.14599
DO - 10.1111/his.14599
M3 - Article
C2 - 34780072
AN - SCOPUS:85122289686
JO - Histopathology
JF - Histopathology
SN - 0309-0167
ER -